Xun Zhang, Justin Schwartz, Venkat K. Ramshesh, Peter Pediaditakis, Ekhson Holmuhamedov, Zhi Zhong, Tom P. Theruvath, John J. Lemasters – 23 December 2009
Nathan M. Bass – 23 December 2009
Michael Kremer, Emmanuel Thomas, Richard J. Milton, Ashley W. Perry, Nico van Rooijen, Michael D. Wheeler, Steven Zacks, Michael Fried, Richard A. Rippe, Ian N. Hines – 23 December 2009 – Hepatosteatosis is associated with increased expression of tumor necrosis factor alpha (TNF‐α) and interleukin (IL)‐12, major T helper (Th) 1 cytokines, and reduced hepatic natural killer T (NKT) cell numbers. The relationship between lipid accumulation, cytokine expression, and hepatic NKT cells is not known.
Alexander Koch, Christian Trautwein – 23 December 2009
William C. Chapman – 23 December 2009
Michelina Nascimbeni, Thomas Montange, Helen K. W. Law, Vincent Mallet, Bertrand Saunier, Yves Rivière, Stanislas Pol – 23 December 2009
Ji‐Yuan Zhang, Zheng Zhang, Fang Lin, Zheng‐Sheng Zou, Ruo‐Nan Xu, Lei Jin, Jun‐Liang Fu, Feng Shi, Ming Shi, Hui‐Fen Wang, Fu‐Sheng Wang – 23 December 2009 – Interleukin‐17 (IL‐17)‐producing CD4+ T cells (Th17)‐mediated immune response has been demonstrated to play a critical role in inflammation‐associated disease; however, its role in chronic hepatitis B virus (HBV) infection remains unknown.
Florian van Bömmel, Robert A. de Man, Heiner Wedemeyer, Katja Deterding, Jörg Petersen, Peter Buggisch, Andreas Erhardt, Dietrich Hüppe, Kerstin Stein, Jörg Trojan, Christoph Sarrazin, Wulf O. Böcher, Ulrich Spengler, Hermann E. Wasmuth, Jurrien G.P.
Robert S. O'Shea, Srinivasan Dasarathy, Arthur J. McCullough, Practice Guideline Committee of the American Association for the Study of Liver Diseases and the Practice Parameters Committee of the American College of Gastroenterology – 23 December 2009
Lauren N. Bell, Janice L. Theodorakis, Raj Vuppalanchi, Romil Saxena, Kerry G. Bemis, Mu Wang, Naga Chalasani – 23 December 2009 – Nonalcoholic fatty liver disease (NAFLD), ranging from relatively benign simple steatosis to progressive nonalcoholic steatohepatitis (NASH) and fibrosis, is an increasingly common chronic liver disease. Liver biopsy is currently the only reliable tool for staging the subtypes of NAFLD; therefore, noninvasive serum biomarkers for evaluation of liver disease and fibrosis are urgently needed.